Literature DB >> 30030624

Performance of the 2016 ACR-EULAR classification criteria for primary Sjogren's syndrome in a Korean cohort.

Jennifer Lee1, Jung Hee Koh1, Ji-Won Kim1, Yoon-Kyoung Sung2, Shin-Seok Lee3, Jung Yoon Choe4, Seung-Cheol Shim5, Hyun-Sook Kim6, Hae-Rim Kim7, Ji-Min Kim8, Sung Ryul Kwon9, Hyun-Ok Kim10, Kichul Shin11, Chang Hoon Lee12, So-Hyang Chung13, Seung-Ki Kwok1, Ji Hyeon Ju1, Sung-Hwan Park14.   

Abstract

This study compared the performance of the newly proposed 2016 American College of Rheumatology (ACR)/European League Against Rheumatism (EULAR) criteria to the 2002 American-European Consensus Group (AECG) and 2012 ACR classification criteria for primary Sjogren's syndrome (pSS) in well-characterized Korean patients. Patients with pSS from 12 university-affiliated hospitals in Korea were enrolled from October 2013 to January 2017. Clinical and laboratory data were reviewed. For the validation set, patients who underwent evaluation tests to rule out pSS at Seoul St. Mary's hospital from November 2016 to December 2017 were analyzed. Baseline registry data were available in 458 patients, and 328 patients had sufficient data to determine the fulfillment of each criteria set. All three sets of criteria were met by 307 patients (93.6%). The newly proposed 2016 ACR/EULAR criteria were met by 325 patients (99.1%). The 2002 AECG and 2012 ACR criteria were met by 325 (99.1%) and 310 patients (94.5%), respectively. In a validation cohort consisting of 161 patients with pSS-related symptoms/signs, the sensitivity and specificity of the 2016 ACR/EULAR criteria were 100% [95% confidence interval (CI), 96.11-100.00] and 81.8% [95% CI, 76.15-94.26], respectively. Agreement between the 2016 criteria and 2012 or 2002 criteria was high (Cohen's kappa 0.736 and 0.769, respectively). The newly proposed 2016 ACR/EULAR criteria were met by most patients diagnosed with pSS according to previous criteria and showed higher sensitivity and lower specificity compared with both previous criteria sets.

Entities:  

Keywords:  Classification criteria; Sjogren’s syndrome

Mesh:

Year:  2018        PMID: 30030624     DOI: 10.1007/s00296-018-4109-y

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN: 0172-8172            Impact factor:   2.631


  32 in total

Review 1.  Classification criteria for Sjögren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group.

Authors:  C Vitali; S Bombardieri; R Jonsson; H M Moutsopoulos; E L Alexander; S E Carsons; T E Daniels; P C Fox; R I Fox; S S Kassan; S R Pillemer; N Talal; M H Weisman
Journal:  Ann Rheum Dis       Date:  2002-06       Impact factor: 19.103

Review 2.  Treatment Guidelines for Rheumatologic Manifestations of Sjögren's Syndrome: Use of Biologic Agents, Management of Fatigue, and Inflammatory Musculoskeletal Pain.

Authors:  Steven E Carsons; Frederick B Vivino; Ann Parke; Nancy Carteron; Vidya Sankar; Richard Brasington; Michael T Brennan; William Ehlers; Robert Fox; Hal Scofield; Katherine M Hammitt; Julius Birnbaum; Stuart Kassan; Steven Mandel
Journal:  Arthritis Care Res (Hoboken)       Date:  2017-03-03       Impact factor: 4.794

3.  Severe Health-Related Quality of Life Impairment in Active Primary Sjögren's Syndrome and Patient-Reported Outcomes: Data From a Large Therapeutic Trial.

Authors:  Divi Cornec; Valérie Devauchelle-Pensec; Xavier Mariette; Sandrine Jousse-Joulin; Jean-Marie Berthelot; Aleth Perdriger; Xavier Puéchal; Véronique Le Guern; Jean Sibilia; Jacques-Eric Gottenberg; Laurent Chiche; Eric Hachulla; Pierre Yves Hatron; Vincent Goeb; Gilles Hayem; Jacques Morel; Charles Zarnitsky; Jean Jacques Dubost; Philippe Saliou; Jacques Olivier Pers; Raphaèle Seror; Alain Saraux
Journal:  Arthritis Care Res (Hoboken)       Date:  2017-04       Impact factor: 4.794

4.  Clinical and laboratory profiles of primary Sjogren's syndrome in a Chinese population: A retrospective analysis of 315 patients.

Authors:  Xiaomei Li; Bei Xu; Yan Ma; Xiangpei Li; Qi Cheng; Ximei Wang; Guosheng Wang; Long Qian; Li Wei
Journal:  Int J Rheum Dis       Date:  2015-04-30       Impact factor: 2.454

5.  Influence of geolocation and ethnicity on the phenotypic expression of primary Sjögren's syndrome at diagnosis in 8310 patients: a cross-sectional study from the Big Data Sjögren Project Consortium.

Authors:  Pilar Brito-Zerón; Nihan Acar-Denizli; Margit Zeher; Astrid Rasmussen; Raphaele Seror; Elke Theander; Xiaomei Li; Chiara Baldini; Jacques-Eric Gottenberg; Debashish Danda; Luca Quartuccio; Roberta Priori; Gabriela Hernandez-Molina; Aike A Kruize; Valeria Valim; Marika Kvarnstrom; Damien Sene; Roberto Gerli; Sonja Praprotnik; David Isenberg; Roser Solans; Maureen Rischmueller; Seung-Ki Kwok; Gunnel Nordmark; Yasunori Suzuki; Roberto Giacomelli; Valerie Devauchelle-Pensec; Michele Bombardieri; Benedikt Hofauer; Hendrika Bootsma; Johan G Brun; Guadalupe Fraile; Steven E Carsons; Tamer A Gheita; Jacques Morel; Cristina Vollenveider; Fabiola Atzeni; Soledad Retamozo; Ildiko Fanny Horvath; Kathy Sivils; Thomas Mandl; Pulukool Sandhya; Salvatore De Vita; Jorge Sanchez-Guerrero; Eefje van der Heijden; Virginia Fernandes Moça Trevisani; Marie Wahren-Herlenius; Xavier Mariette; Manuel Ramos-Casals
Journal:  Ann Rheum Dis       Date:  2016-11-29       Impact factor: 19.103

6.  Anti-La positive, anti-Ro negative subset of primary Sjögren's syndrome: anti-La is a reality but is the disease?

Authors:  Debashish Danda; Rohan Sharma; Dat Truong; Kristi A Koelsch; Biji T Kurien; Harini Bagavant; Umesh Deshmukh; C Erick Kaufman; David M Lewis; Donald U Stone; Lida Radfar; Astrid Rasmussen; Kathy L Sivils; Robert H Scofield
Journal:  Clin Exp Rheumatol       Date:  2017-02-20       Impact factor: 4.473

Review 7.  Sjögren's syndrome.

Authors:  Robert I Fox
Journal:  Lancet       Date:  2005 Jul 23-29       Impact factor: 79.321

8.  Comparison of the American-European Consensus Group Sjogren's syndrome classification criteria to newly proposed American College of Rheumatology criteria in a large, carefully characterised sicca cohort.

Authors:  Astrid Rasmussen; John A Ice; He Li; Kiely Grundahl; Jennifer A Kelly; Lida Radfar; Donald U Stone; Kimberly S Hefner; Juan-Manuel Anaya; Michael Rohrer; Rajaram Gopalakrishnan; Glen D Houston; David M Lewis; James Chodosh; John B Harley; Pamela Hughes; Jacen S Maier-Moore; Courtney G Montgomery; Nelson L Rhodus; A Darise Farris; Barbara M Segal; Roland Jonsson; Christopher J Lessard; R Hal Scofield; Kathy L Moser Sivils
Journal:  Ann Rheum Dis       Date:  2013-08-22       Impact factor: 19.103

9.  2016 American College of Rheumatology/European League Against Rheumatism classification criteria for primary Sjögren's syndrome: A consensus and data-driven methodology involving three international patient cohorts.

Authors:  Caroline H Shiboski; Stephen C Shiboski; Raphaèle Seror; Lindsey A Criswell; Marc Labetoulle; Thomas M Lietman; Astrid Rasmussen; Hal Scofield; Claudio Vitali; Simon J Bowman; Xavier Mariette
Journal:  Ann Rheum Dis       Date:  2016-10-26       Impact factor: 19.103

10.  Level of agreement between 2002 American-European Consensus Group and 2012 American College of Rheumatology classification criteria for Sjögren's syndrome and reasons for discrepancies.

Authors:  Divi Cornec; Alain Saraux; Béatrice Cochener; Jacques-Olivier Pers; Sandrine Jousse-Joulin; Yves Renaudineau; Thierry Marhadour; Valérie Devauchelle-Pensec
Journal:  Arthritis Res Ther       Date:  2014-03-19       Impact factor: 5.156

View more
  2 in total

1.  Correlations between salivary gland scintigraphy and histopathologic data of salivary glands in patients with primary Sjogren's syndrome.

Authors:  Ji-Won Kim; Roh Jin; Jae Ho Han; Jeong-Hyun Kang; Ju-Yang Jung; Chang-Hee Suh; Young-Sil An; Hyoun-Ah Kim
Journal:  Clin Rheumatol       Date:  2022-06-30       Impact factor: 3.650

2.  Associations of Anti-Aquaporin 5 Autoantibodies with Serologic and Histopathological Features of Sjögren's Syndrome.

Authors:  Sumin Jeon; Jennifer Lee; Sung-Hwan Park; Hyun-Duck Kim; Youngnim Choi
Journal:  J Clin Med       Date:  2019-11-03       Impact factor: 4.241

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.